Quick Comparison
| BPC-157 | Bronchogen | |
|---|---|---|
| Half-Life | 4 hours (stable in gastric juice) | Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure |
| Typical Dosage | Standard: 200-800 mcg subcutaneous once daily, or 500-1000 mcg oral once daily. Often cycled 4-6 weeks on, 2 weeks off. Injectable may be administered near the injury site for localized healing. Oral route used primarily for gut-related conditions. | Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Standard Khavinson pulse-dosing protocol. |
| Administration | Subcutaneous injection, intramuscular injection, or oral | Oral capsule or subcutaneous injection (cycled) |
| Research Papers | 30 papers | 5 papers |
| Categories |
Mechanism of Action
BPC-157
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. Its mechanism of action is remarkably multifaceted, affecting multiple organ systems and healing pathways simultaneously, which is unusual for a single peptide. The primary mechanism centers on the nitric oxide (NO) system — BPC-157 modulates both constitutive (eNOS) and inducible (iNOS) nitric oxide synthase, and can either promote or inhibit NO production depending on the tissue context and injury state.
BPC-157's regenerative effects are mediated through upregulation of multiple growth factors. It increases expression of vascular endothelial growth factor (VEGF), promoting angiogenesis — the formation of new blood vessels at injury sites, which is critical for delivering oxygen and nutrients for tissue repair. It also upregulates epidermal growth factor (EGF), nerve growth factor (NGF), and hepatocyte growth factor (HGF) receptors, supporting wound healing, nerve regeneration, and organ protection respectively. In tendon and ligament injuries, BPC-157 stimulates fibroblast migration and proliferation, accelerating collagen deposition and organized tissue repair rather than scar formation.
Beyond structural healing, BPC-157 has significant effects on the central and enteric nervous systems. It modulates dopaminergic, serotonergic, GABAergic, and opioid systems, which may explain reported effects on mood, gut function, and pain perception. It protects endothelial function, counteracts the effects of NSAIDs on the gastric mucosa, and has demonstrated cytoprotective effects in models of liver, brain, heart, and intestinal damage. The peptide also interacts with the FAK-paxillin pathway, which is central to cell adhesion and migration during wound healing. Its stability in gastric juice — unusual for a peptide — enables oral administration, making it one of the few peptides effective by both injectable and oral routes.
Bronchogen
Bronchogen is a Khavinson tetrapeptide (Ala-Glu-Asp-Leu) positioned as the respiratory-system bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the family-wide framework: tissue-derived short peptides preferentially target the same tissue type from which they were originally identified, binding to gene promoter sequences and modulating expression of tissue-specific genes.
For bronchogen, proposed targets include genes regulating bronchial epithelial cell proliferation and differentiation, surfactant production by alveolar type II cells, ciliary function in airway epithelium, and local immune regulation in respiratory mucosa. Russian research has reported bronchogen-induced improvements in lung function markers in animal models of chronic respiratory injury and in elderly populations with age-related pulmonary decline. Cellular studies have suggested effects on mucociliary clearance and reductions in airway inflammation markers.
As with all Khavinson cytogens and cytamins, the evidence base is concentrated in Russian gerontology and pulmonology research traditions with limited independent Western validation. Bronchogen is not a substitute for evidence-based treatment of asthma, chronic obstructive pulmonary disease, or other diagnosed respiratory conditions, and its role in respiratory health should be considered exploratory rather than established. The brief plasma half-life (around 30 minutes) reflects the family-wide model of transient signalling triggering longer-lasting transcriptional effects.
Risks & Safety
BPC-157
Common
nausea, dizziness, mild headache, injection site irritation.
Serious
no completed human studies, so long-term effects are unestablished.
Rare
allergic reactions, theoretical concern about promoting new blood vessel growth in existing tumors.
Bronchogen
Common
generally well tolerated in Russian observational studies.
Serious
very limited Western clinical data; not a substitute for evidence-based treatment of asthma, COPD, or other chronic respiratory disease.
Rare
allergic reactions.
Full Profiles
BPC-157 →
A healing compound made from a protein found in stomach fluid. It's the most studied peptide for tissue repair, with research showing it helps heal tendons, ligaments, muscles, the gut, and other organs. It's stable enough to survive stomach acid, so you can take it either by injection under the skin or by mouth.
Bronchogen →
A Khavinson tetrapeptide (Ala-Glu-Asp-Leu) developed in Russia as a tissue-specific bioregulator targeting the lungs and respiratory tract. Promoted for chronic respiratory conditions, age-related decline in lung function, and recovery from respiratory illness. Like the other Khavinson cytamins, the evidence base is dominated by Russian research and not independently validated in Western clinical practice.